« Back to Record
Citation APA

Kim, T. W., Burris, H. H., de Miguel Luken, M. J., Pishvaian, M. M., Bang, Y. J., Gordon, M., Awada, A., Camidge, D. R., Hodi, F. S., McArthur, G. A., Miller, W. W., Cervantes, A., Chow, L. Q. M. L., Lesokhin, A. A., Rutten, A., Sznol, M., Rishipathak, D., Chen, S. C., Stefanich, E., Pourmohamad, T., Anderson, M., Kim, J., Huseni, M., Rhee, I., & Siu, L. L. Y. L. (2022). First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Clinical cancer research, 28(16), 3452-3463. doi:10.1158/1078-0432.CCR-21-4020


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/372584

Kim, T. W., Burris, H. H., de Miguel Luken, M. J., Pishvaian, M. M., Bang, Y. J., Gordon, M., Awada, A., Camidge, D. R., Hodi, F. S., McArthur, G. A., Miller, W. W., Cervantes, A., Chow, L. Q. M. L., Lesokhin, A. A., Rutten, A., Sznol, M., Rishipathak, D., Chen, S. C., Stefanich, E., Pourmohamad, T., Anderson, M., Kim, J., Huseni, M., Rhee, I., & Siu, L. L. Y. L. (2022). First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Clinical cancer research, 28(16), 3452-3463. doi:10.1158/1078-0432.CCR-21-4020